Feature | December 23, 2013

PCI Performance Measures Include Patient Selection, Appropriateness

Measures examine care before, during, after procedure

December 23, 2013 — Careful documentation of patient selection and procedure appropriateness are critical — yet underutilized — steps in ensuring high-quality clinical care for percutaneous coronary intervention (PCI), according to performance measures released by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society for Cardiovascular Angiography and Interventions (SCAI), the AMA-Convened Physician Consortium for Performance Improvement and the National Committee for Quality Assurance (NCQA).
Designed to benchmark and improve the quality of PCI, the set of performance measures includes 11 measures that address both ambulatory and inpatient settings, with two measures that address documentation and appropriateness. The document focuses primarily on elective PCI.
The new set of measures breaks important ground for performance measurement examining care before, during and after the procedure. It is the first set of cardiovascular performance measures to directly address procedure appropriateness. In addition, the measures incorporate other indicators of quality such as procedural volume and whether the institution benchmarks care by participating in regional or national registries.
The 11 measures are:
  1. Comprehensive documentation of the reasons for PCI
  2. An appropriate reason for elective PCI  (benefits outweigh the risks)  
  3. An evaluation of the individual’s ability to receive dual antiplatelet therapy (conducted before the procedure)
  4. The use of embolic protection devices in the treatment of saphenous vein bypass graft disease
  5. An assessment of renal function before the procedure (including glomerular filtration rate) and the documentation of contrast used during the procedure
  6. Documentation of the radiation dose used during the procedure
  7. The prescription of optimal medical therapy at discharge (aspirin, PY12 inhibitors and statins)   
  8. A referral to an outpatient cardiac rehabilitation program (to reduce the risk of recurrent events)   
  9. Participation in a regional or national PCI registry  
  10. The average annual volume of PCIs performed by the physician over the last two calendars years
  11. The average annual volume of PCIs performed by the hospital over the last calendar year
Measures 1, 3, 5, 7, 8, 9 and 11 are performance measures, while 2, 4, 6, and 10 are quality metrics. Quality metrics may not meet all specifications of formal performance measures or may be associated with unintended consequences of public reporting.
According to the writing committee, the measures may “serve as vehicles to accelerate appropriate translation of scientific evidence into clinical practice.” The committee goal was to create measures that capture many important aspects of quality while minimizing the reporting burden.
“Hospitals and health systems are increasingly facing a burden with measurement across multiple conditions and services,” said Carl Tommaso, M.D., interventional cardiologist, NorthShore University HealthSystem, and writing committee co-chair. “We wanted to focus on those aspects of PCI care that we thought would give us the greatest yield in terms of improving patient care.”
Brahmajee Nallamothu, M.D., associate professor of cardiovascular medicine, Department of Internal Medicine, University of Michigan, and writing committee co-chair, said this document is the first step in the evolving process of performance measurement.  
“Through these measures, we have moved beyond simple measurement of a few treatments to incorporating key concepts like appropriateness,” said Nallamothu. “There is still much more work to be done, however, and an important part of this process was to identify important areas for future investigation.”
The committee identified four areas of research that will generate better performance measures in the future:
  1. Measuring the filling of prescriptions (not just the prescription of drugs) and optimal dosing
  2. Better utilizing current data systems to track PCI quality
  3. Building accountability by all practitioners involved into quality metrics
  4. Utilizing patient surveys to track performance
The 2013 Performance Measures for Adults Undergoing Percutaneous Coronary Intervention is available on the ACC website and AHA websites and in future print issues of Journal of the American College of Cardiology (JACC) and Circulation: Journal of the American Heart Association.
For more information: www.cardiosource.org, www.americanheart.org

Related Content

Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Avinger, Pantheris atherectomy catheter, OCT, Lumivascular technology, expanded FDA indication, diagnostic imaging device
News | Atherectomy Devices| October 20, 2016
Avinger Inc. recently announced that the company has received expanded indications from the U.S. Food and Drug...
recall, alligator retrieval device, X-Celerator hydrophilic guidewire, UltraFlow flow directed micro catheters, Marathon flow directed micro catheters
News | Cath Lab| October 18, 2016
Medtronic plc announced last week that it has notified customers of a voluntary recall of certain lots of its Pipeline...
Inventory management, Cardinal, RFID inventory tracking, cath lab inventory
Sponsored Content | Whitepapers | Inventory Management| October 18, 2016
As healthcare moves into the era of bundled payments, providers need to be especially focused on ensuring delivery of
angioseal, angio-seal, terumo, St. Jude, vascular closure devices
News | Vascular Closure Devices| October 18, 2016
October 18, 2016 — Abbott and St. Jude Medical Inc.
3-D bioprinting, 3-D printing, printed organs, 3D bioprinting

3-D printed vessel made from living cells implanted in an animal to test feasibility of using such structures clinically. Blood vessels are a stepping stone to the creation of more complex 3-D printed organs made from biomaterials. Image from the South Carolina Project for Organ Biofabrication.


Feature | 3-D Printing| October 13, 2016 | Dave Fornell
The U.S. Food and Drug Administration (FDA) changed its rules concerning custom medical devices Oct.
Shockwave lithoplasty system, VIVA 16, Vascular Interventioanl Advances, VIA Physicians, late-breaking endovascular clinical trial results
News | Cath Lab| October 12, 2016
VIVA (Vascular Interventional Advances) Physicians announced a number of highly anticipated late-breaking clinical...
Terumo Finecross, guidewires, guide wires, guidewires 101, basics of guidewire technology

An illustration of Terumo's Finecross guidewire crossing a tight lesion. 

Feature | Guidewires| October 12, 2016 | Dave Fornell
While guidewires are a key tool used by
Medtronic, FDA clearance, TrailBlazer peripheral angled support catheter, PAD, peripheral artery disease
Technology | Peripheral Arterial Disease (PAD)| October 12, 2016
Medtronic plc announced recently that the U.S. Food and Drug Administration (FDA) has cleared the TrailBlazer angled...
Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano
News | Heart Valve Technology| October 10, 2016
Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and...
Overlay Init